



**Newron Pharmaceuticals S.p.A. announces data of phase I clinical trials of Its anti-epileptic and anti-parkinson compound NW-1015**

Newron Pharmaceuticals announces the completion of two phase I trials of its antiepileptic and anti-parkinson compound NW-1015. Single ascending dose and steady state at three doses have been successfully completed in 32 healthy volunteers. The drug has demonstrated excellent tolerability and bioavailability with linear pharmacokinetics. Dose finding studies for both anti-parkinson and anticonvulsant activity are scheduled to begin in the coming months.

NW-1015 is a unique novel molecule combining in itself Na- and Ca-channel modulatory activity together with Monoamine Oxidase B inhibition. These pharmacodynamic properties together with its excellent pharmacokinetics and the preferential concentration within the CNS, are at the basis of the drug's efficacy in animal models of seizures, Parkinson's disease, pain and cerebral ischemia